AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, announced on 5/25/18 positive overall survival (OS) results for the Phase III PACIFIC trial, a randomized, double-blinded, placebo-controlled, multi-center trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).